AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 220.87B +40.4% |
| Revenue (ttm) | 45.77B +9.9% |
| Net Income | 7.87B +33.7% |
| EPS | 5.03 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 28.32 |
| Forward PE | 17.97 |
| Dividend | 2.36 (1.66%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 6,890,000 |
| Open | 12,388 |
| Previous Close | 14,240 |
| Day's Range | 12,388 - 13,354 |
| 52-Week Range | 10,178 - 15,732 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 16,330.34 (+22.29%) |
| Earnings Date | Jul 27, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 16,330p, which is an increase of 22.29% from the latest price.
News
AstraZeneca (AZN) Faces Setback as Phase 3 Study Misses Key Endpoint
AstraZeneca (AZN) Faces Setback as Phase 3 Study Misses Key Endpoint
Ionis Pharmaceuticals price target lowered to $94 from $108 at TD Cowen
TD Cowen lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $94 from $108 and keeps a Buy rating on the shares after the company and AstraZeneca’s (AZN) CARDIO-TTRansform…
Is AstraZeneca (AZN) Stock a Buy on Today’s Dip? Here’s What Analysts Have to Say About That
AstraZeneca stock was down on Thursday after it reported a failed clinical trial, but this could present a buying opportunity for investors.
AZN Stock Update: Key Market Insights for Investors
AZN Stock Update: Key Market Insights for Investors
AstraZeneca Slides 9.9% After Heart Drug Trial Misses Late-Stage Goal
AstraZeneca Slides 9.9% After Heart Drug Trial Misses Late-Stage Goal
Morning Movers: Ionis and AstraZeneca sink after trial misses endpoint
Markets are attempting to recover this morning after Wednesday’s geopolitical-driven selloff, with U.S. stock futures moving modestly higher as oil prices retreat from recent highs. Nasdaq futures are...
BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) Surge After AstraZeneca Trial Setback
BridgeBio Pharma (BBIO) and Alnylam Pharma (ALNY) Surge After AstraZeneca Trial Setback
Why AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jump
AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing.
5 Things to Know Before the Stock Market Opens on Thursday
Stock futures are slightly higher this morning as investors monitor developments in the Middle East; PepsiCo's results narrowly beat Wall Street estimates as strength in international markets offset s...
UK stocks decline as AstraZeneca tumbles after trial setback
The UK's FTSE 100 declined on Thursday as investors assessed renewed tensions in the Middle East, while pharmaceutical heavyweight AstraZeneca weighed heavily on the benchmark after reporting disappoi...
Stocks making the biggest moves premarket: AstraZeneca, PepsiCo, Salesforce, Levi & more
These are the stocks posting the largest moves in the premarket.
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
London's FTSE 100 slips as Middle East tensions persist, AstraZeneca drags
The UK's FTSE 100 slipped on Thursday as investors grappled with renewed Middle East tensions, with heavyweight AstraZeneca adding to the pressure after reporting disappointing results from a late-sta...
Why Is AstraZeneca Stock (AZN) Falling Today?
AstraZeneca ($AZN) shares fell 9.5% in pre-market trading today after the biotech company said that its experimental heart drug, Wainua (eplontersen), failed to meet the primary endpoint in a late-sta...
AstraZeneca (AZN) Faces Setback in Phase III Cardiomyopathy Trial
AstraZeneca (AZN) Faces Setback in Phase III Cardiomyopathy Trial
AstraZeneca Falls After Wainua Heart Disease Trial Fails
AstraZeneca Falls After Wainua Heart Disease Trial Fails
AstraZeneca (AZN) Shares Plunge Following Trial Setback
AstraZeneca (AZN) Shares Plunge Following Trial Setback
Major drugmaker loses $27 billion in market value after failed trial
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
AstraZeneca (AZN) Shares Drop 9% Following Disappointing Clinical Trial Results
AstraZeneca (AZN) Shares Drop 9% Following Disappointing Clinical Trial Results
Ionis, AstraZeneca report CARDIO-TTRansform trial misses primary endpoint
Ionis Pharmaceuticals (IONS) and partner AstraZeneca (AZN) announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not mee...
AstraZeneca says CARDIO-TTRansform trial did not meet primary efficacy endpoint
The CARDIO-TTRansform Phase III trial for AstraZeneca (AZN) and Ionis’ (IONS) Wainua in patients with transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint of the co...
AstraZeneca shares plunge as Wainua fails late-stage heart disease trial
AstraZeneca shares slumped nearly 10% on Thursday after the drugmaker said its nerve disease treatment Wainua failed to achieve the primary objective in a late-stage clinical trial for a serious heart...
Ionis And AstraZeneca's CARDIO-TTRansform Trial Of Eplontersen In ATTR-CM Misses Primary Endpoint
(RTTNews) - Ionis Pharmaceuticals Inc. (IONS) and AstraZeneca announced results from the Phase 3 CARDIO-TTRansform trial of Eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy (AT...
AstraZeneca stock dives 9% after heart drug trial misses target
AstraZeneca stock dives 9% after heart drug trial misses target
AstraZeneca Says Wainua Trial Failed to Meet Primary Goal
The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a placebo.